Novartis announced the first study results from the phase III PLATINUM clinical development program assessing the safety and efficacy of QMF149, an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol acetate (IND - a long acting beta agonist [LABA]) and mometasone furoate (MF - an anti-inflammatory [ICS]).
Transgene announces that the last patient has been included in the phase 2 trial evaluating TG4010 in combination with Opdivo (nivolumab) and chemotherapy as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with low or no expression of PD-L1 by the tumor cells.
Pfizer’s Lyrica (pregabalin) failed to meet the primary endpoint in a phase 3 trial evaluating it as an adjunctive therapy for epilepsy patients with primary generalized tonic-clonic (PGTC) seizures.
OncoSec Medical, a late-stage cancer biotechnology company developing intratumoral gene-delivery immunotherapies, announced that the first patient has been dosed in TRIFECTA, a triple combination clinical trial of OncoSec's TAVO, an IDO1 drug (epacadostat) and KEYTRUDA in patients with unresectable squamous cell carcinoma head and neck (SCCHN) cancer.
Novartis said that IND/GLY/MF (QVM149), a new inhaled combination treatment, showed significant improvements over current standard-of-care inhaled treatment and placebo in two phase 2 trials in patients with asthma.
In an oral presentation from the Digestive Disease Week medical conference in San Diego, California today, Eli Lilly and Company (NYSE: LLY) announced new safety and efficacy data for mirikizumab in patients with moderately- to severely active Crohn's disease.
SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in the Phase 3 “DeFi” (Desmoid/Fibromatosis) trial evaluating nirogacestat, an oral, selective, small molecule gamma-secretase inhibitor, in adult patients with progressing desmoid tumors.
New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a potential anti-inflammatory reliever in mild asthma.
AbbVie has discontinued an ongoing phase 3 trial evaluating its antibody drug conjugate (ADC) depatuxizumab mafodotin (Depatux-M) for the treatment of newly diagnosed glioblastoma (GBM), an aggressive type of brain cancer, owing to futility.
Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and older with moderate to severe atopic dermatitis (AD).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.